{"protocolSection": {"identificationModule": {"nctId": "NCT01691859", "orgStudyIdInfo": {"id": "115666"}, "secondaryIdInfos": [{"id": "2012-001643-51", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "GlaxoSmithKline", "class": "INDUSTRY"}, "briefTitle": "MEA112997 Open-label Long Term Extension Safety Study of Mepolizumab in Asthmatic Subjects", "officialTitle": "MEA115666: A Multi-centre, Open-label, Long Term Safety Study of Mepolizumab in Asthmatic Subjects Who Participated in the MEA112997 Trial"}, "statusModule": {"statusVerifiedDate": "2023-06", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": true, "nctId": "NCT00244686", "statusForNctId": "NO_LONGER_AVAILABLE"}, "startDateStruct": {"date": "2012-09-28", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2017-05-31", "type": "ACTUAL"}, "completionDateStruct": {"date": "2017-05-31", "type": "ACTUAL"}, "studyFirstSubmitDate": "2012-09-13", "studyFirstSubmitQcDate": "2012-09-20", "studyFirstPostDateStruct": {"date": "2012-09-25", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2018-04-19", "resultsFirstSubmitQcDate": "2018-04-19", "resultsFirstPostDateStruct": {"date": "2018-05-22", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2023-06-09", "lastUpdatePostDateStruct": {"date": "2023-06-28", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "GlaxoSmithKline", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "This is a multi-centre, open-label long term safety study of 100 milligrams (mg) mepolizumab administered subcutaneously (SC) in addition to standard of care in subjects who participated in the MEA112997 study. At each clinic visit, adverse events will be assessed and exacerbations will also be reviewed."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["extension study", "Severe refractory asthma", "safety", "SB-240563", "mepolizumab", "eosinophils"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 347, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Mepolizumab", "type": "EXPERIMENTAL", "description": "Subjects will receive 100 mg of mepolizumab (in 1ml polypropylene syringe) injected subcutaneously (SC) approximately every 4 weeks.", "interventionNames": ["Drug: Mepolizumab"]}], "interventions": [{"type": "DRUG", "name": "Mepolizumab", "description": "100 mg of mepolizumab will be injected subcutaneously (SC) once every 4 weeks", "armGroupLabels": ["Mepolizumab"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number of Participants Who Experienced On-treatment Adverse Events (AE) and On-treatment Serious Adverse Events (SAE)", "description": "AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with use of a medicinal product (MP), whether or not considered related to MP. AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with use of MP. SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or is medically significant or all events of possible drug induced liver injury with hyperbilirubinemia. As Treated (AT) Population consisted of participants who received at least one dose of open label mepolizumab. On-treatment AEs and on-treatment SAEs are the events occurring on/after the first dose of open-label mepolizumab date and before/on last dose of mepolizumab + 28 days.", "timeFrame": "Baseline (Week 0) to Week 240"}], "secondaryOutcomes": [{"measure": "Number of Participants Who Experienced On-treatment Systemic (i.e., Allergic/Immunoglobulin E [IgE]-Mediated and Non-allergic) and On-treatment Local Site Reactions", "description": "Systemic and local site reactions following mepolizumab dosing as identified by the investigator and the number of participants who experienced systemic and/or local site reactions are presented. On-treatment AEs and on-treatment SAEs are the events occurring on/after the first dose of open-label mepolizumab date and before/on last dose of mepolizumab + 28 days.", "timeFrame": "Baseline (Week 0) to Week 240"}, {"measure": "Mean Change From Baseline in QT Interval Corrected by Bazett's Method (QTc[B])", "description": "Twelve-lead ECGs were performed at Screening and every 24 weeks during the treatment period. ECG measurements were made after the participant had rested in the supine position for 5 minutes. Collection shortly after a meal or during sleep was avoided as QT prolongation can occur at these times. Baseline was the last available ECG prior to mepolizumab dosing. Change from Baseline was post-Baseline values minus Baseline values. Only those participants available at the specified time points were analyzed represented by n=X in the category titles.", "timeFrame": "Baseline (Week 0) to Week 240"}, {"measure": "Mean Change From Baseline in QT Interval Corrected by Fridericia's Method (QTc[F])", "description": "Twelve-lead ECGs were performed at Screening and every 24 weeks during the treatment period. ECG measurements were made after the participant had rested in the supine position for 5 minutes. Collection shortly after a meal or during sleep was avoided as QT prolongation can occur at these times. Baseline was the last available ECG prior to mepolizumab dosing. Change from Baseline was post-Baseline values minus Baseline values. Only those participants available at the specified time points were analyzed represented by n=X in the category titles.", "timeFrame": "Baseline (Week 0) to Week 240"}, {"measure": "Number of Participants With a Maximum Change From Baseline for QTc(F) and QTc(B)", "description": "Twelve-lead ECGs were performed at Screening and every 24 weeks during the treatment period. ECG measurements were made after the participant had rested in the supine position for 5 minutes. Collection shortly after a meal or during sleep was avoided as QT prolongation can occur at these times. Baseline was the last available ECG prior to mepolizumab dosing. Change from Baseline was post-Baseline values minus Baseline values. Number of participants with a maximum change from Baseline for QTc(F) and QTc(B) at any time post Baseline are presented. Only those participants who provided ECG data at baseline and post-baseline were analyzed.", "timeFrame": "Baseline (Week 0) to Week 240"}, {"measure": "Number of Participants With Clinical Chemistry Data of Potential Clinical Concern", "description": "Clinical chemistry analytes with laboratory ranges defining values of potential clinical concern included sodium, potassium, calcium, phosphate, serum glucose and alanine aminotransferase. Number of participants with clinical chemistry abnormalities of potential clinical concern anytime post baseline are presented. Only those participants who provided lab data post-baseline were analyzed represented by n=X in the category titles.", "timeFrame": "Baseline (Week 0) to Week 240"}, {"measure": "Number of Participants With Hematology Data of Potential Clinical Concern", "description": "Hematology parameters with laboratory ranges defining values of potential clinical concern included hemoglobin, hematocrit, platelet count, white blood cell count. Number of participants with clinical hematology abnormalities of potential clinical concern anytime post baseline are presented, which only included participants with low hemoglobin values. Only those participants who provided lab data post-baseline were analyzed.", "timeFrame": "Baseline (Week 0) to Week 240"}, {"measure": "Mean Change From Baseline in Vital Signs-Sitting Diastolic Blood Pressure and Sitting Systolic Blood Pressure", "description": "Vital signs included sitting pulse rate and sitting blood pressure (diastolic and systolic). Measurements were done pre injection with the participant sitting, having rested in this position for at least 5 minutes before each reading. Baseline was Week 0. Change from Baseline was post-Baseline values minus Baseline values. Only those participants available at the specified time points were analyzed represented by n=X in the category titles.", "timeFrame": "Baseline (Week 0) to Week 240"}, {"measure": "Mean Change From Baseline in Vital Signs-Sitting Pulse Rate", "description": "Vital signs included sitting pulse rate and blood pressure (diastolic and systolic). Measurements were done pre injection with the participant sitting, having rested in this position for at least 5 minutes before each reading. Baseline was Week 0. Change from Baseline was post-Baseline values minus Baseline values. Only those participants available at the specified time points were analyzed represented by n=X in the category titles.", "timeFrame": "Baseline (Week 0) to Week 240"}, {"measure": "Annualized Rate of On-treatment Exacerbations", "description": "Exacerbations were defined as worsening of asthma which required use of systemic corticosteroids and/or hospitalization and/or Emergency Department visits. Data is presented as mean which is exacerbation rate/year. Exacerbation data are performed using a negative binomial model with covariates of region, annualized rate of exacerbations in the interval between MEA112997 and MEA115666 (as an ordinal variable) and baseline % predicted FEV1, and with logarithm of time on treatment as an offset variable.", "timeFrame": "Baseline (Week 0) to Week 240"}, {"measure": "Mean Change From Baseline in Asthma Control Questionnaire (ACQ) Score", "description": "The ACQ-5 is a five-item questionnaire, which was developed as a measure of participant' asthma control that was completed by the participant. The five questions enquire about the frequency and/or severity of symptoms (nocturnal awakening on waking in the morning, activity limitation, and shortness of breath, wheeze). The ACQ consists of 5 questions that are scored on a 7 point scale from 0 (totally controlled) to 6 (severely uncontrolled). The ACQ score was derived as mean of five questions: ACQ score = Question 1 (Q1)+Q2+Q3+Q4+Q5 divided by 5 where Q1, Q2,... Q5 are the scores of Q1, Q2, ..., Q5, respectively. The total score ranged from zero (no impairment/limitation) which indicated best condition to six (total impairment/ limitation) which indicated worst asthma. Baseline was Week 0. Change from Baseline was post-Baseline values minus Baseline values. Only those participants available at the specified time points were analyzed represented by n=X in the category titles.", "timeFrame": "Baseline (Week 0) to Week 240"}, {"measure": "Mean Change From Baseline in Clinic Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1)", "description": "FEV1 is forced expiratory volume in the first second. The volume of air that can be forced out in one second after taking a deep breath, an important measure of pulmonary function. Forced expiratory volume (FEV) measures how much air a person can exhale during a forced breath. FEV1 was measured by clinic spirometry. Baseline was Week 0. Change from Baseline was post-Baseline values minus Baseline values. Only those participants available at the specified time points were analyzed represented by n=X in the category titles.", "timeFrame": "Baseline (Week 0) to Week 240"}, {"measure": "Number of Participants With Positive Anti-mepolizumab Binding Antibodies (ADA) and Neutralizing Antibodies (NAb)", "description": "Immunogenicity testing included two types of assays: a binding antibody assay (anti-drug antibody; ADA) and a neutralizing antibody (NAb) assay for participants who were tested positive in the ADA assay. Blood samples were collected for the determination of anti-mepolizumab antibodies, just prior to administration of mepolizumab. Samples that test positive for anti-mepolizumab antibodies were further tested for the presence of neutralizing antibody. Number of participants with positive highest value post-Baseline have been presented. Only those participants available at the specified time points were analyzed represented by n=X in the category titles.", "timeFrame": "Baseline (Week 0) to Week 240"}, {"measure": "Number of Participants Who Withdrew Due to Lack of Efficacy", "description": "Lack of efficacy referred to failure of expected pharmacological action of Mepolizumab. Number of participants who withdrew due to lack of efficacy are presented.", "timeFrame": "Baseline (Week 0) to Week 240"}, {"measure": "Number of Participants Requiring Hospitalizations Due to Adverse Events Including Asthma Exacerbations", "description": "AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or is medically significant or all events of possible drug induced liver injury with hyperbilirubinemia. Number of participants requiring hospitalization due to an on-treatment serious adverse event including asthma exacerbations are presented. On-treatment SAEs are the events occurring on/after the first dose of open-label mepolizumab date and before/on last dose of mepolizumab + 28 days.", "timeFrame": "Baseline (Week 0) to Week 240"}, {"measure": "Number of Participants Who Withdrew Due to AE", "description": "AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or is medically significant or all events of possible drug induced liver injury with hyperbilirubinemia. Number of participants who withdrew due to AE are presented.", "timeFrame": "Baseline (Week 0) to Week 240"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Informed Consent.\n* MEA112997 Study Participation: Received at least 2 doses of double-blind investigational product during the MEA112997 trial.\n* MEA112997 Treatment Assignment: If the subject received mepolizumab, they must have had a positive risk: benefit ratio.\n* Currently being treated with a controller medication and the subject has been on a controller medication for the past 12 weeks.\n* Male or Eligible Female Subjects. To be eligible for entry into the study, females of childbearing potential must commit to consistent and correct use of an acceptable method of birth control for the duration of the trial and for 4 months after the last study drug administration.\n\nExclusion Criteria:\n\n* Hypersensitivity related to mepolizumab.\n* Clinically significant change in health status since completing participation in the MEA112997 trial.\n* A current malignancy or previous history of cancer in remission for less than 12 months prior to screening.\n* For those subjects who had a SAE in MEA112997 that was assessed as possibly related to mepolizumab by the investigator.\n* Subjects who are pregnant or breastfeeding. Subjects should not be enrolled if they plan to become pregnant during the time of study participation.\n* Screening ECG which has a clinically significant abnormality.\n* Received Xolair (omalizumab) within the past 130 days.\n* Participated in a clinical trial within the past 30 days or have received investigational medication within five terminal half-lives of Screen Visit, whichever is longer.\n* Current smokers.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "GSK Clinical Trials", "affiliation": "GlaxoSmithKline", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "GSK Investigational Site", "city": "Long Beach", "state": "California", "zip": "90808", "country": "United States", "geoPoint": {"lat": 33.76696, "lon": -118.18923}}, {"facility": "GSK Investigational Site", "city": "Riverside", "state": "California", "zip": "92506", "country": "United States", "geoPoint": {"lat": 33.95335, "lon": -117.39616}}, {"facility": "GSK Investigational Site", "city": "Denver", "state": "Colorado", "zip": "80206", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "GSK Investigational Site", "city": "New Haven", "state": "Connecticut", "zip": "06520", "country": "United States", "geoPoint": {"lat": 41.30815, "lon": -72.92816}}, {"facility": "GSK Investigational Site", "city": "Albany", "state": "Georgia", "zip": "31707", "country": "United States", "geoPoint": {"lat": 31.57851, "lon": -84.15574}}, {"facility": "GSK Investigational Site", "city": "Lexington", "state": "Kentucky", "zip": "40508", "country": "United States", "geoPoint": {"lat": 37.98869, "lon": -84.47772}}, {"facility": "GSK Investigational Site", "city": "Winston-Salem", "state": "North Carolina", "zip": "27103", "country": "United States", "geoPoint": {"lat": 36.09986, "lon": -80.24422}}, {"facility": "GSK Investigational Site", "city": "Cleveland", "state": "Ohio", "zip": "44195", "country": "United States", "geoPoint": {"lat": 41.4995, "lon": -81.69541}}, {"facility": "GSK Investigational Site", "city": "Hershey", "state": "Pennsylvania", "zip": "17033", "country": "United States", "geoPoint": {"lat": 40.28592, "lon": -76.65025}}, {"facility": "GSK Investigational Site", "city": "Pittsburgh", "state": "Pennsylvania", "zip": "15213", "country": "United States", "geoPoint": {"lat": 40.44062, "lon": -79.99589}}, {"facility": "GSK Investigational Site", "city": "Nashville", "state": "Tennessee", "zip": "37212", "country": "United States", "geoPoint": {"lat": 36.16589, "lon": -86.78444}}, {"facility": "GSK Investigational Site", "city": "Mar del Plata", "state": "Buenos Aires", "zip": "B7600FZN", "country": "Argentina", "geoPoint": {"lat": -38.00228, "lon": -57.55754}}, {"facility": "GSK Investigational Site", "city": "Ciudad Aut\u00f3noma de Buenos Aires", "zip": "C1121ABE", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "GSK Investigational Site", "city": "Ciudad Aut\u00f3noma de Buenos Aires", "zip": "C1426ABP", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "GSK Investigational Site", "city": "Mendoza", "zip": "M5500CCG", "country": "Argentina", "geoPoint": {"lat": -32.89084, "lon": -68.82717}}, {"facility": "GSK Investigational Site", "city": "New Lambton", "state": "New South Wales", "zip": "2305", "country": "Australia", "geoPoint": {"lat": -32.95, "lon": 151.68333}}, {"facility": "GSK Investigational Site", "city": "Adelaide", "state": "South Australia", "zip": "5000", "country": "Australia", "geoPoint": {"lat": -34.92866, "lon": 138.59863}}, {"facility": "GSK Investigational Site", "city": "Clayton", "state": "Victoria", "zip": "3168", "country": "Australia", "geoPoint": {"lat": -37.91667, "lon": 145.11667}}, {"facility": "GSK Investigational Site", "city": "Melbourne", "state": "Victoria", "zip": "3004", "country": "Australia", "geoPoint": {"lat": -37.814, "lon": 144.96332}}, {"facility": "GSK Investigational Site", "city": "Nedlands", "state": "Western Australia", "zip": "6009", "country": "Australia", "geoPoint": {"lat": -31.98184, "lon": 115.8073}}, {"facility": "GSK Investigational Site", "city": "Calgary", "state": "Alberta", "zip": "T2N 4Z6", "country": "Canada", "geoPoint": {"lat": 51.05011, "lon": -114.08529}}, {"facility": "GSK Investigational Site", "city": "Vancouver", "state": "British Columbia", "zip": "V5Z 1M9", "country": "Canada", "geoPoint": {"lat": 49.24966, "lon": -123.11934}}, {"facility": "GSK Investigational Site", "city": "Mississauga", "state": "Ontario", "zip": "L5A 3V4", "country": "Canada", "geoPoint": {"lat": 43.5789, "lon": -79.6583}}, {"facility": "GSK Investigational Site", "city": "Quebec City", "state": "Quebec", "zip": "G1V 4G5", "country": "Canada", "geoPoint": {"lat": 46.81228, "lon": -71.21454}}, {"facility": "GSK Investigational Site", "city": "Puente Alto - Santiago", "state": "Regi\u00f3n Metro De Santiago", "zip": "8207257", "country": "Chile"}, {"facility": "GSK Investigational Site", "city": "Valparaiso", "state": "Valpara\u00edso", "zip": "2341131", "country": "Chile", "geoPoint": {"lat": -33.03932, "lon": -71.62725}}, {"facility": "GSK Investigational Site", "city": "Santiago", "zip": "8380453", "country": "Chile", "geoPoint": {"lat": -33.45694, "lon": -70.64827}}, {"facility": "GSK Investigational Site", "city": "Talcahuano", "zip": "4270918", "country": "Chile", "geoPoint": {"lat": -36.72494, "lon": -73.11684}}, {"facility": "GSK Investigational Site", "city": "Le Kremlin-Bic\u00eatre Cedex", "zip": "94275", "country": "France", "geoPoint": {"lat": 48.81471, "lon": 2.36073}}, {"facility": "GSK Investigational Site", "city": "Marseille cedex 20", "zip": "13915", "country": "France", "geoPoint": {"lat": 43.29551, "lon": 5.38958}}, {"facility": "GSK Investigational Site", "city": "Montpellier cedex 5", "zip": "34295", "country": "France", "geoPoint": {"lat": 43.61092, "lon": 3.87723}}, {"facility": "GSK Investigational Site", "city": "Saint Pierre cedex", "zip": "97448", "country": "France"}, {"facility": "GSK Investigational Site", "city": "Ruedersdorf", "state": "Brandenburg", "zip": "15562", "country": "Germany", "geoPoint": {"lat": 51.1, "lon": 11.45}}, {"facility": "GSK Investigational Site", "city": "Frankfurt am Main", "state": "Hessen", "zip": "60596", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"facility": "GSK Investigational Site", "city": "Frankfurt", "state": "Hessen", "zip": "60596", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"facility": "GSK Investigational Site", "city": "Mainz", "state": "Rheinland-Pfalz", "zip": "55131", "country": "Germany", "geoPoint": {"lat": 49.98419, "lon": 8.2791}}, {"facility": "GSK Investigational Site", "city": "Luebeck", "state": "Schleswig-Holstein", "zip": "23552", "country": "Germany", "geoPoint": {"lat": 53.86893, "lon": 10.68729}}, {"facility": "GSK Investigational Site", "city": "Berlin", "zip": "10367", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "GSK Investigational Site", "city": "Berlin", "zip": "10717", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "GSK Investigational Site", "city": "Magdeburg", "zip": "39120", "country": "Germany", "geoPoint": {"lat": 52.12773, "lon": 11.62916}}, {"facility": "GSK Investigational Site", "city": "Cheongju, Chungcheongbuk-do", "zip": "361-711", "country": "Korea, Republic of"}, {"facility": "GSK Investigational Site", "city": "Suwon, Kyonggi-do", "zip": "443-721", "country": "Korea, Republic of", "geoPoint": {"lat": 37.29111, "lon": 127.00889}}, {"facility": "GSK Investigational Site", "city": "Lodz", "zip": "90-153", "country": "Poland", "geoPoint": {"lat": 51.75, "lon": 19.46667}}, {"facility": "GSK Investigational Site", "city": "Wroclaw", "zip": "54-239", "country": "Poland", "geoPoint": {"lat": 51.1, "lon": 17.03333}}, {"facility": "GSK Investigational Site", "city": "Bucharest", "zip": "011461", "country": "Romania", "geoPoint": {"lat": 44.43225, "lon": 26.10626}}, {"facility": "GSK Investigational Site", "city": "Bucharest", "zip": "050159", "country": "Romania", "geoPoint": {"lat": 44.43225, "lon": 26.10626}}, {"facility": "GSK Investigational Site", "city": "Iasi", "zip": "700115", "country": "Romania", "geoPoint": {"lat": 47.16667, "lon": 27.6}}, {"facility": "GSK Investigational Site", "city": "Targu Mures", "zip": "540143", "country": "Romania", "geoPoint": {"lat": 46.54245, "lon": 24.55747}}, {"facility": "GSK Investigational Site", "city": "Barnaul", "zip": "656 045", "country": "Russian Federation", "geoPoint": {"lat": 53.36056, "lon": 83.76361}}, {"facility": "GSK Investigational Site", "city": "Chelyabinsk", "zip": "454106", "country": "Russian Federation", "geoPoint": {"lat": 55.15402, "lon": 61.42915}}, {"facility": "GSK Investigational Site", "city": "Kazan", "zip": "420008", "country": "Russian Federation", "geoPoint": {"lat": 55.78874, "lon": 49.12214}}, {"facility": "GSK Investigational Site", "city": "Moscow", "zip": "105 077", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "GSK Investigational Site", "city": "Moscow", "zip": "123182", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "GSK Investigational Site", "city": "Saint-Petersburg", "zip": "194354", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "GSK Investigational Site", "city": "St'Petersburg", "zip": "191015", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "GSK Investigational Site", "city": "Dnipropetrovsk", "zip": "49051", "country": "Ukraine", "geoPoint": {"lat": 48.4593, "lon": 35.03864}}, {"facility": "GSK Investigational Site", "city": "Donetsk", "zip": "83099", "country": "Ukraine", "geoPoint": {"lat": 48.023, "lon": 37.80224}}, {"facility": "GSK Investigational Site", "city": "Kharkiv", "zip": "61035", "country": "Ukraine", "geoPoint": {"lat": 49.98081, "lon": 36.25272}}, {"facility": "GSK Investigational Site", "city": "Kiev", "zip": "03680", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "GSK Investigational Site", "city": "Kyiv", "zip": "03038", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "GSK Investigational Site", "city": "Leicester", "state": "Leicestershire", "zip": "LE3 9QP", "country": "United Kingdom", "geoPoint": {"lat": 52.6386, "lon": -1.13169}}, {"facility": "GSK Investigational Site", "city": "London", "zip": "EC1M 6BQ", "country": "United Kingdom", "geoPoint": {"lat": 51.50853, "lon": -0.12574}}, {"facility": "GSK Investigational Site", "city": "London", "zip": "SW3 6HP", "country": "United Kingdom", "geoPoint": {"lat": 51.50853, "lon": -0.12574}}, {"facility": "GSK Investigational Site", "city": "Manchester", "zip": "M23 9LT", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "GSK Investigational Site", "city": "Southampton", "zip": "SO16 6YD", "country": "United Kingdom", "geoPoint": {"lat": 50.90395, "lon": -1.40428}}]}, "referencesModule": {"references": [{"pmid": "30359681", "type": "BACKGROUND", "citation": "Khatri S, Moore W, Gibson PG, Leigh R, Bourdin A, Maspero J, Barros M, Buhl R, Howarth P, Albers FC, Bradford ES, Gilson M, Price RG, Yancey SW, Ortega H. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J Allergy Clin Immunol. 2019 May;143(5):1742-1751.e7. doi: 10.1016/j.jaci.2018.09.033. Epub 2018 Oct 23."}, {"pmid": "30954640", "type": "DERIVED", "citation": "Ortega HG, Meyer E, Brusselle G, Asano K, Prazma CM, Albers FC, Mallett SA, Yancey SW, Gleich GJ. Update on immunogenicity in severe asthma: Experience with mepolizumab. J Allergy Clin Immunol Pract. 2019 Sep-Oct;7(7):2469-2475.e1. doi: 10.1016/j.jaip.2019.03.042. Epub 2019 Apr 5. No abstract available."}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/", "infoTypes": ["STUDY_PROTOCOL", "SAP", "ICF", "CSR"], "timeFrame": "Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.", "accessCriteria": "Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.", "url": "https://www.gsk.com/en-gb/innovation/trials/data-transparency/"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "A total of 362 participants were screened; 4 participants were screen failures (did not meet the inclusion/exclusion criteria); 11 participants were withdrawn during the run-in period (4 did not meet the continuation criteria, 4 withdrawal by participant and 3 following physician decision).", "recruitmentDetails": "This was a multi-center, open-label, long term safety study of mepolizumab in 347 asthmatic participants who participated in the MEA112997 trial and were found eligible for this study after screening and run in phase. The study was conducted at 65 centers in 13 countries from 28 Sep 2012 to 31 May 2017.", "groups": [{"id": "FG000", "title": "Mepolizumab 100 mg", "description": "Participants received 100 milligram (mg) of mepolizumab injected subcutaneously (SC) once every 4 weeks until participant withdrawal or mepolizumab becomes commercially available in the relevant participating country. Participants remained on standard of care asthma therapy, which was adjusted during the study, at the discretion of their physician."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "347"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "347"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "19"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "11"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "4"}]}, {"type": "Product commercially available", "reasons": [{"groupId": "FG000", "numSubjects": "221"}]}, {"type": "Study closed/terminated", "reasons": [{"groupId": "FG000", "numSubjects": "50"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "5"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "6"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "31"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Mepolizumab 100 mg", "description": "Participants received 100 mg of mepolizumab injected SC once every 4 weeks until participant withdrawal or mepolizumab becomes commercially available in the relevant participating country. Participants remained on standard of care asthma therapy, which was adjusted during the study, at the discretion of their physician."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "347"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "52.2", "spread": "10.73"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "224"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "123"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "African American/African Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "8"}]}]}, {"title": "American Indian or Alaskan Native", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}]}]}, {"title": "Asian - Central/South Asian Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "4"}]}]}, {"title": "Asian - East Asian Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "14"}]}]}, {"title": "White - Arabic/North African Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "7"}]}]}, {"title": "White - White/Caucasian/European Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "311"}]}]}, {"title": "Asian & Native Hawaiian or Other Pacific Islander", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Number of Participants Who Experienced On-treatment Adverse Events (AE) and On-treatment Serious Adverse Events (SAE)", "description": "AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with use of a medicinal product (MP), whether or not considered related to MP. AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with use of MP. SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or is medically significant or all events of possible drug induced liver injury with hyperbilirubinemia. As Treated (AT) Population consisted of participants who received at least one dose of open label mepolizumab. On-treatment AEs and on-treatment SAEs are the events occurring on/after the first dose of open-label mepolizumab date and before/on last dose of mepolizumab + 28 days.", "populationDescription": "AT Population.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Baseline (Week 0) to Week 240", "groups": [{"id": "OG000", "title": "Mepolizumab 100 mg", "description": "Participants received 100 mg of mepolizumab injected SC once every 4 weeks until participant withdrawal or mepolizumab becomes commercially available in the relevant participating country. Participants remained on standard of care asthma therapy, which was adjusted during the study, at the discretion of their physician."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "347"}]}], "classes": [{"title": "AE", "categories": [{"measurements": [{"groupId": "OG000", "value": "326"}]}]}, {"title": "SAE", "categories": [{"measurements": [{"groupId": "OG000", "value": "79"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants Who Experienced On-treatment Systemic (i.e., Allergic/Immunoglobulin E [IgE]-Mediated and Non-allergic) and On-treatment Local Site Reactions", "description": "Systemic and local site reactions following mepolizumab dosing as identified by the investigator and the number of participants who experienced systemic and/or local site reactions are presented. On-treatment AEs and on-treatment SAEs are the events occurring on/after the first dose of open-label mepolizumab date and before/on last dose of mepolizumab + 28 days.", "populationDescription": "AT Population.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Baseline (Week 0) to Week 240", "groups": [{"id": "OG000", "title": "Mepolizumab 100 mg", "description": "Participants received 100 mg of mepolizumab injected SC once every 4 weeks until participant withdrawal or mepolizumab becomes commercially available in the relevant participating country. Participants remained on standard of care asthma therapy, which was adjusted during the study, at the discretion of their physician."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "347"}]}], "classes": [{"title": "Systemic reactions", "categories": [{"measurements": [{"groupId": "OG000", "value": "9"}]}]}, {"title": "Local site reactions", "categories": [{"measurements": [{"groupId": "OG000", "value": "42"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline in QT Interval Corrected by Bazett's Method (QTc[B])", "description": "Twelve-lead ECGs were performed at Screening and every 24 weeks during the treatment period. ECG measurements were made after the participant had rested in the supine position for 5 minutes. Collection shortly after a meal or during sleep was avoided as QT prolongation can occur at these times. Baseline was the last available ECG prior to mepolizumab dosing. Change from Baseline was post-Baseline values minus Baseline values. Only those participants available at the specified time points were analyzed represented by n=X in the category titles.", "populationDescription": "AT Population.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Milliseconds", "timeFrame": "Baseline (Week 0) to Week 240", "groups": [{"id": "OG000", "title": "Mepolizumab 100 mg", "description": "Participants received 100 mg of mepolizumab injected SC once every 4 weeks until participant withdrawal or mepolizumab becomes commercially available in the relevant participating country. Participants remained on standard of care asthma therapy, which was adjusted during the study, at the discretion of their physician."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "347"}]}], "classes": [{"title": "Week 24, n=330", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "330"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.2", "spread": "18.57"}]}]}, {"title": "Week 48, n=319", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "319"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.2", "spread": "17.19"}]}]}, {"title": "Week 72, n=307", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "307"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.5", "spread": "16.76"}]}]}, {"title": "Week 96, n=293", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "293"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.3", "spread": "17.92"}]}]}, {"title": "Week 124, n=292", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "292"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.5", "spread": "19.69"}]}]}, {"title": "Week 148, n=275", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "275"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.6", "spread": "17.84"}]}]}, {"title": "Week 176, n=201", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "201"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.6", "spread": "18.02"}]}]}, {"title": "Week 200, n=149", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "149"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.3", "spread": "17.02"}]}]}, {"title": "Week 228, n=32", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "32"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.5", "spread": "20.95"}]}]}, {"title": "Follow up, n=270", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "270"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.5", "spread": "18.71"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline in QT Interval Corrected by Fridericia's Method (QTc[F])", "description": "Twelve-lead ECGs were performed at Screening and every 24 weeks during the treatment period. ECG measurements were made after the participant had rested in the supine position for 5 minutes. Collection shortly after a meal or during sleep was avoided as QT prolongation can occur at these times. Baseline was the last available ECG prior to mepolizumab dosing. Change from Baseline was post-Baseline values minus Baseline values. Only those participants available at the specified time points were analyzed represented by n=X in the category titles.", "populationDescription": "AT Population.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Milliseconds", "timeFrame": "Baseline (Week 0) to Week 240", "groups": [{"id": "OG000", "title": "Mepolizumab 100 mg", "description": "Participants received 100 mg of mepolizumab injected SC once every 4 weeks until participant withdrawal or mepolizumab becomes commercially available in the relevant participating country. Participants remained on standard of care asthma therapy, which was adjusted during the study, at the discretion of their physician."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "347"}]}], "classes": [{"title": "Week 24, n=330", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "330"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "5.1", "spread": "17.00"}]}]}, {"title": "Week 48, n=319", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "319"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.1", "spread": "15.72"}]}]}, {"title": "Week 72, n=307", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "307"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.2", "spread": "15.11"}]}]}, {"title": "Week 96, n=293", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "293"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.2", "spread": "15.37"}]}]}, {"title": "Week 124, n=292", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "292"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.2", "spread": "16.77"}]}]}, {"title": "Week 148, n=275", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "275"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.9", "spread": "15.49"}]}]}, {"title": "Week 176, n=201", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "201"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.0", "spread": "15.97"}]}]}, {"title": "Week 200, n=149", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "149"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.3", "spread": "14.52"}]}]}, {"title": "Week 228, n=32", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "32"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.4", "spread": "15.81"}]}]}, {"title": "Follow up, n=270", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "270"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.9", "spread": "16.39"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With a Maximum Change From Baseline for QTc(F) and QTc(B)", "description": "Twelve-lead ECGs were performed at Screening and every 24 weeks during the treatment period. ECG measurements were made after the participant had rested in the supine position for 5 minutes. Collection shortly after a meal or during sleep was avoided as QT prolongation can occur at these times. Baseline was the last available ECG prior to mepolizumab dosing. Change from Baseline was post-Baseline values minus Baseline values. Number of participants with a maximum change from Baseline for QTc(F) and QTc(B) at any time post Baseline are presented. Only those participants who provided ECG data at baseline and post-baseline were analyzed.", "populationDescription": "AT Population.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Baseline (Week 0) to Week 240", "groups": [{"id": "OG000", "title": "Mepolizumab 100 mg", "description": "Participants received 100 mg of mepolizumab injected SC once every 4 weeks until participant withdrawal or mepolizumab becomes commercially available in the relevant participating country. Participants remained on standard of care asthma therapy, which was adjusted during the study, at the discretion of their physician."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "342"}]}], "classes": [{"title": "QTc(F): < -60", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "QTc(F): >= -60 - < -30", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "QTc(F): >= -30 - < 0", "categories": [{"measurements": [{"groupId": "OG000", "value": "31"}]}]}, {"title": "QTc(F): >= 0 - < 30", "categories": [{"measurements": [{"groupId": "OG000", "value": "252"}]}]}, {"title": "QTc(F): >= 30 - < 60", "categories": [{"measurements": [{"groupId": "OG000", "value": "55"}]}]}, {"title": "QTc(F): >= 60", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}]}]}, {"title": "QTc(B): < -60", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "QTc(B): >= -60 - < -30", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "QTc(B): >= -30 - < 0", "categories": [{"measurements": [{"groupId": "OG000", "value": "36"}]}]}, {"title": "QTc(B): >= 0 - < 30", "categories": [{"measurements": [{"groupId": "OG000", "value": "228"}]}]}, {"title": "QTc(B): >= 30 - < 60", "categories": [{"measurements": [{"groupId": "OG000", "value": "69"}]}]}, {"title": "QTc(B): >= 60", "categories": [{"measurements": [{"groupId": "OG000", "value": "8"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Clinical Chemistry Data of Potential Clinical Concern", "description": "Clinical chemistry analytes with laboratory ranges defining values of potential clinical concern included sodium, potassium, calcium, phosphate, serum glucose and alanine aminotransferase. Number of participants with clinical chemistry abnormalities of potential clinical concern anytime post baseline are presented. Only those participants who provided lab data post-baseline were analyzed represented by n=X in the category titles.", "populationDescription": "AT Population.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Baseline (Week 0) to Week 240", "groups": [{"id": "OG000", "title": "Mepolizumab 100 mg", "description": "Participants received 100 mg of mepolizumab injected SC once every 4 weeks until participant withdrawal or mepolizumab becomes commercially available in the relevant participating country. Participants remained on standard of care asthma therapy, which was adjusted during the study, at the discretion of their physician."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "346"}]}], "classes": [{"title": "Potassium high, n=346", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Serum glucose high, n=346", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Serum glucose low, n=346", "categories": [{"measurements": [{"groupId": "OG000", "value": "7"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Hematology Data of Potential Clinical Concern", "description": "Hematology parameters with laboratory ranges defining values of potential clinical concern included hemoglobin, hematocrit, platelet count, white blood cell count. Number of participants with clinical hematology abnormalities of potential clinical concern anytime post baseline are presented, which only included participants with low hemoglobin values. Only those participants who provided lab data post-baseline were analyzed.", "populationDescription": "AT Population.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Baseline (Week 0) to Week 240", "groups": [{"id": "OG000", "title": "Mepolizumab 100 mg", "description": "Participants received 100 mg of mepolizumab injected SC once every 4 weeks until participant withdrawal or mepolizumab becomes commercially available in the relevant participating country. Participants remained on standard of care asthma therapy, which was adjusted during the study, at the discretion of their physician."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "346"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline in Vital Signs-Sitting Diastolic Blood Pressure and Sitting Systolic Blood Pressure", "description": "Vital signs included sitting pulse rate and sitting blood pressure (diastolic and systolic). Measurements were done pre injection with the participant sitting, having rested in this position for at least 5 minutes before each reading. Baseline was Week 0. Change from Baseline was post-Baseline values minus Baseline values. Only those participants available at the specified time points were analyzed represented by n=X in the category titles.", "populationDescription": "AT Population.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Millimeters of mercury (mmHg)", "timeFrame": "Baseline (Week 0) to Week 240", "groups": [{"id": "OG000", "title": "Mepolizumab 100 mg", "description": "Participants received 100 mg of mepolizumab injected SC once every 4 weeks until participant withdrawal or mepolizumab becomes commercially available in the relevant participating country. Participants remained on standard of care asthma therapy, which was adjusted during the study, at the discretion of their physician."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "347"}]}], "classes": [{"title": "Sitting Diastolic Blood Pressure: Week 4, n=346", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "346"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.0", "spread": "8.71"}]}]}, {"title": "Sitting Diastolic Blood Pressure: Week 8, n=345", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "345"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.5", "spread": "8.85"}]}]}, {"title": "Sitting Diastolic Blood Pressure: Week 12, n=342", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "342"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.7", "spread": "9.67"}]}]}, {"title": "Sitting Diastolic Blood Pressure: Week 16, n=341", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "341"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.6", "spread": "9.27"}]}]}, {"title": "Sitting Diastolic Blood Pressure: Week 20, n=338", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "338"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.6", "spread": "9.17"}]}]}, {"title": "Sitting Diastolic Blood Pressure: Week 24, n=336", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "336"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.7", "spread": "9.27"}]}]}, {"title": "Sitting Diastolic Blood Pressure: Week 28, n=332", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "332"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.3", "spread": "8.90"}]}]}, {"title": "Sitting Diastolic Blood Pressure: Week 32, n=333", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "333"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.0", "spread": "9.62"}]}]}, {"title": "Sitting Diastolic Blood Pressure: Week 36, n=329", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "329"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.8", "spread": "8.95"}]}]}, {"title": "Sitting Diastolic Blood Pressure: Week 40, n=329", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "329"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.2", "spread": "9.33"}]}]}, {"title": "Sitting Diastolic Blood Pressure: Week 44, n=326", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "326"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.1", "spread": "10.00"}]}]}, {"title": "Sitting Diastolic Blood Pressure: Week 48, n=325", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "325"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.7", "spread": "9.67"}]}]}, {"title": "Sitting Diastolic Blood Pressure: Week 52, n=322", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "322"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.1", "spread": "9.85"}]}]}, {"title": "Sitting Diastolic Blood Pressure: Week 56, n=320", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "320"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.3", "spread": "9.67"}]}]}, {"title": "Sitting Diastolic Blood Pressure: Week 60, n=318", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "318"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.9", "spread": "9.56"}]}]}, {"title": "Sitting Diastolic Blood Pressure: Week 64, n=318", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "318"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.0", "spread": "9.29"}]}]}, {"title": "Sitting Diastolic Blood Pressure: Week 68, n=317", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "317"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.1", "spread": "9.94"}]}]}, {"title": "Sitting Diastolic Blood Pressure: Week 72, n=312", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "312"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.5", "spread": "9.67"}]}]}, {"title": "Sitting Diastolic Blood Pressure: Week 76, n=313", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "313"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.1", "spread": "10.06"}]}]}, {"title": "Sitting Diastolic Blood Pressure: Week 80, n=311", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "311"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.6", "spread": "10.23"}]}]}, {"title": "Sitting Diastolic Blood Pressure: Week 84, n=310", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "310"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.7", "spread": "10.51"}]}]}, {"title": "Sitting Diastolic Blood Pressure: Week 88, n=310", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "310"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.4", "spread": "10.45"}]}]}, {"title": "Sitting Diastolic Blood Pressure: Week 92, n=311", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "311"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.0", "spread": "9.89"}]}]}, {"title": "Sitting Diastolic Blood Pressure: Week 96, n=303", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "303"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.2", "spread": "9.81"}]}]}, {"title": "Sitting Diastolic Blood Pressure: Week 100, n=300", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "300"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.3", "spread": "9.40"}]}]}, {"title": "Sitting Diastolic Blood Pressure: Week 104, n=301", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "301"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.0", "spread": "9.69"}]}]}, {"title": "Sitting Diastolic Blood Pressure: Week 108, n=300", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "300"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.9", "spread": "10.28"}]}]}, {"title": "Sitting Diastolic Blood Pressure: Week 112, n=299", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "299"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.9", "spread": "9.78"}]}]}, {"title": "Sitting Diastolic Blood Pressure: Week 116, n=297", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "297"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.7", "spread": "9.56"}]}]}, {"title": "Sitting Diastolic Blood Pressure: Week 120, n=295", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "295"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.8", "spread": "9.41"}]}]}, {"title": "Sitting Diastolic Blood Pressure: Week 124, n=294", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "294"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.3", "spread": "10.52"}]}]}, {"title": "Sitting Diastolic Blood Pressure: Week 128, n=293", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "293"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.2", "spread": "10.08"}]}]}, {"title": "Sitting Diastolic Blood Pressure: Week 132, n=289", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "289"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.0", "spread": "10.48"}]}]}, {"title": "Sitting Diastolic Blood Pressure: Week 136, n=288", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "288"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.7", "spread": "10.42"}]}]}, {"title": "Sitting Diastolic Blood Pressure: Week 140, n=287", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "287"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.6", "spread": "9.90"}]}]}, {"title": "Sitting Diastolic Blood Pressure: Week 144, n=290", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "290"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.9", "spread": "9.83"}]}]}, {"title": "Sitting Diastolic Blood Pressure: Week 148, n=287", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "287"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.1", "spread": "10.22"}]}]}, {"title": "Sitting Diastolic Blood Pressure: Week 152, n=284", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "284"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.9", "spread": "10.17"}]}]}, {"title": "Sitting Diastolic Blood Pressure: Week 156, n=275", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "275"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.4", "spread": "10.44"}]}]}, {"title": "Sitting Diastolic Blood Pressure: Week 160, n=265", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "265"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.6", "spread": "9.93"}]}]}, {"title": "Sitting Diastolic Blood Pressure: Week 164, n=242", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "242"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.7", "spread": "10.83"}]}]}, {"title": "Sitting Diastolic Blood Pressure: Week 168, n=232", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "232"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.3", "spread": "10.46"}]}]}, {"title": "Sitting Diastolic Blood Pressure: Week 172, n=226", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "226"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.2", "spread": "10.18"}]}]}, {"title": "Sitting Diastolic Blood Pressure: Week 176, n=212", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "212"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.6", "spread": "9.84"}]}]}, {"title": "Sitting Diastolic Blood Pressure: Week 180, n=200", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "200"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.6", "spread": "10.42"}]}]}, {"title": "Sitting Diastolic Blood Pressure: Week 184, n=184", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "184"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.3", "spread": "9.94"}]}]}, {"title": "Sitting Diastolic Blood Pressure: Week 188, n=180", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "180"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.4", "spread": "9.81"}]}]}, {"title": "Sitting Diastolic Blood Pressure: Week 192, n=176", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "176"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.1", "spread": "10.25"}]}]}, {"title": "Sitting Diastolic Blood Pressure: Week 196, n=175", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "175"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.5", "spread": "10.18"}]}]}, {"title": "Sitting Diastolic Blood Pressure: Week 200, n=172", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "172"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.4", "spread": "10.07"}]}]}, {"title": "Sitting Diastolic Blood Pressure: Week 204, n=169", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "169"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.1", "spread": "10.25"}]}]}, {"title": "Sitting Diastolic Blood Pressure: Week 208, n=157", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "157"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.8", "spread": "9.48"}]}]}, {"title": "Sitting Diastolic Blood Pressure: Week 212, n=146", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "146"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.3", "spread": "9.53"}]}]}, {"title": "Sitting Diastolic Blood Pressure: Week 216, n=130", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "130"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.2", "spread": "9.55"}]}]}, {"title": "Sitting Diastolic Blood Pressure: Week 220, n=67", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "67"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.6", "spread": "10.85"}]}]}, {"title": "Sitting Diastolic Blood Pressure: Week 224, n=54", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "54"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.9", "spread": "11.97"}]}]}, {"title": "Sitting Diastolic Blood Pressure: Week 228, n=37", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "37"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.2", "spread": "9.60"}]}]}, {"title": "Sitting Diastolic Blood Pressure: Week 232, n=5", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.6", "spread": "5.86"}]}]}, {"title": "Sitting Diastolic Blood Pressure: Follow-up, n=306", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "306"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.7", "spread": "10.03"}]}]}, {"title": "Sitting Systolic Blood Pressure: Week 4, n=346", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "346"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.2", "spread": "10.79"}]}]}, {"title": "Sitting Systolic Blood Pressure: Week 8, n=345", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "345"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.7", "spread": "12.57"}]}]}, {"title": "Sitting Systolic Blood Pressure: Week 12, n=342", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "342"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.3", "spread": "12.59"}]}]}, {"title": "Sitting Systolic Blood Pressure: Week 16, n=341", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "341"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.5", "spread": "13.60"}]}]}, {"title": "Sitting Systolic Blood Pressure: Week 20, n=338", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "338"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.8", "spread": "13.31"}]}]}, {"title": "Sitting Systolic Blood Pressure: Week 24, n=336", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "336"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.8", "spread": "13.93"}]}]}, {"title": "Sitting Systolic Blood Pressure: Week 28, n=332", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "332"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.6", "spread": "13.61"}]}]}, {"title": "Sitting Systolic Blood Pressure: Week 32, n=333", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "333"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.0", "spread": "14.24"}]}]}, {"title": "Sitting Systolic Blood Pressure: Week 36, n=329", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "329"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.7", "spread": "14.19"}]}]}, {"title": "Sitting Systolic Blood Pressure: Week 40, n=329", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "329"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.6", "spread": "14.11"}]}]}, {"title": "Sitting Systolic Blood Pressure: Week 44, n=326", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "326"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.9", "spread": "14.87"}]}]}, {"title": "Sitting Systolic Blood Pressure: Week 48, n=325", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "325"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.1", "spread": "13.59"}]}]}, {"title": "Sitting Systolic Blood Pressure: Week 52, n=322", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "322"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.3", "spread": "13.63"}]}]}, {"title": "Sitting Systolic Blood Pressure: Week 56, n=320", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "320"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.3", "spread": "14.33"}]}]}, {"title": "Sitting Systolic Blood Pressure: Week 60, n=318", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "318"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.0", "spread": "14.21"}]}]}, {"title": "Sitting Systolic Blood Pressure: Week 64, n=318", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "318"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.2", "spread": "13.99"}]}]}, {"title": "Sitting Systolic Blood Pressure: Week 68, n=317", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "317"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.1", "spread": "14.83"}]}]}, {"title": "Sitting Systolic Blood Pressure: Week 72, n=312", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "312"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.8", "spread": "13.16"}]}]}, {"title": "Sitting Systolic Blood Pressure: Week 76, n=313", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "313"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.8", "spread": "14.44"}]}]}, {"title": "Sitting Systolic Blood Pressure: Week 80, n=311", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "311"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.1", "spread": "14.49"}]}]}, {"title": "Sitting Systolic Blood Pressure: Week 84, n=310", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "310"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.9", "spread": "14.47"}]}]}, {"title": "Sitting Systolic Blood Pressure: Week 88, n=310", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "310"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.7", "spread": "14.94"}]}]}, {"title": "Sitting Systolic Blood Pressure: Week 92, n=311", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "311"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.3", "spread": "15.16"}]}]}, {"title": "Sitting Systolic Blood Pressure: Week 96, n=303", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "303"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.1", "spread": "14.32"}]}]}, {"title": "Sitting Systolic Blood Pressure: Week 100, n=300", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "300"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.7", "spread": "14.71"}]}]}, {"title": "Sitting Systolic Blood Pressure: Week 104, n=301", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "301"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.3", "spread": "14.81"}]}]}, {"title": "Sitting Systolic Blood Pressure: Week 108, n=300", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "300"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.5", "spread": "15.15"}]}]}, {"title": "Sitting Systolic Blood Pressure: Week 112, n=299", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "299"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.4", "spread": "14.83"}]}]}, {"title": "Sitting Systolic Blood Pressure: Week 116, n=297", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "297"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.4", "spread": "14.31"}]}]}, {"title": "Sitting Systolic Blood Pressure: Week 120, n=295", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "295"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.5", "spread": "14.37"}]}]}, {"title": "Sitting Systolic Blood Pressure: Week 124, n=294", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "294"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.7", "spread": "14.80"}]}]}, {"title": "Sitting Systolic Blood Pressure: Week 128, n=293", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "293"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.7", "spread": "14.68"}]}]}, {"title": "Sitting Systolic Blood Pressure: Week 132, n=289", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "289"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.7", "spread": "14.51"}]}]}, {"title": "Sitting Systolic Blood Pressure: Week 136, n=288", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "288"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.9", "spread": "16.81"}]}]}, {"title": "Sitting Systolic Blood Pressure: Week 140, n=287", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "287"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.3", "spread": "15.48"}]}]}, {"title": "Sitting Systolic Blood Pressure: Week 144, n=290", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "290"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.1", "spread": "15.79"}]}]}, {"title": "Sitting Systolic Blood Pressure: Week 148, n=287", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "287"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.8", "spread": "13.59"}]}]}, {"title": "Sitting Systolic Blood Pressure: Week 152, n=284", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "284"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.2", "spread": "15.53"}]}]}, {"title": "Sitting Systolic Blood Pressure: Week 156, n=275", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "275"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.8", "spread": "14.56"}]}]}, {"title": "Sitting Systolic Blood Pressure: Week 160, n=265", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "265"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.1", "spread": "15.34"}]}]}, {"title": "Sitting Systolic Blood Pressure: Week 164, n=242", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "242"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.6", "spread": "15.51"}]}]}, {"title": "Sitting Systolic Blood Pressure: Week 168, n=232", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "232"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.1", "spread": "14.87"}]}]}, {"title": "Sitting Systolic Blood Pressure: Week 172, n=226", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "226"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.8", "spread": "15.67"}]}]}, {"title": "Sitting Systolic Blood Pressure: Week 176, n=212", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "212"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.4", "spread": "13.78"}]}]}, {"title": "Sitting Systolic Blood Pressure: Week 180, n=200", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "200"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.6", "spread": "15.32"}]}]}, {"title": "Sitting Systolic Blood Pressure: Week 184, n=184", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "184"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.5", "spread": "16.36"}]}]}, {"title": "Sitting Systolic Blood Pressure: Week 188, n=180", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "180"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.0", "spread": "15.54"}]}]}, {"title": "Sitting Systolic Blood Pressure: Week 192, n=176", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "176"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.2", "spread": "16.60"}]}]}, {"title": "Sitting Systolic Blood Pressure: Week 196, n=175", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "175"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.8", "spread": "14.76"}]}]}, {"title": "Sitting Systolic Blood Pressure: Week 200, n=172", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "172"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.1", "spread": "15.28"}]}]}, {"title": "Sitting Systolic Blood Pressure: Week 204, n=169", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "169"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.4", "spread": "15.64"}]}]}, {"title": "Sitting Systolic Blood Pressure: Week 208, n=157", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "157"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.0", "spread": "16.92"}]}]}, {"title": "Sitting Systolic Blood Pressure: Week 212, n=146", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "146"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.5", "spread": "14.98"}]}]}, {"title": "Sitting Systolic Blood Pressure: Week 216, n=130", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "130"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.4", "spread": "15.52"}]}]}, {"title": "Sitting Systolic Blood Pressure: Week 220, n=67", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "67"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-4.2", "spread": "20.86"}]}]}, {"title": "Sitting Systolic Blood Pressure: Week 224, n=54", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "54"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-3.8", "spread": "17.87"}]}]}, {"title": "Sitting Systolic Blood Pressure: Week 228, n=37", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "37"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-3.6", "spread": "15.15"}]}]}, {"title": "Sitting Systolic Blood Pressure: Week 232, n=5", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.8", "spread": "6.30"}]}]}, {"title": "Sitting Systolic Blood Pressure: Follow-up, n=306", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "306"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.0", "spread": "14.92"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline in Vital Signs-Sitting Pulse Rate", "description": "Vital signs included sitting pulse rate and blood pressure (diastolic and systolic). Measurements were done pre injection with the participant sitting, having rested in this position for at least 5 minutes before each reading. Baseline was Week 0. Change from Baseline was post-Baseline values minus Baseline values. Only those participants available at the specified time points were analyzed represented by n=X in the category titles.", "populationDescription": "AT Population.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Beats per minute", "timeFrame": "Baseline (Week 0) to Week 240", "groups": [{"id": "OG000", "title": "Mepolizumab 100 mg", "description": "Participants received 100 mg of mepolizumab injected SC once every 4 weeks until participant withdrawal or mepolizumab becomes commercially available in the relevant participating country. Participants remained on standard of care asthma therapy, which was adjusted during the study, at the discretion of their physician."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "347"}]}], "classes": [{"title": "Sitting Pulse Rate: Week 4, n=346", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "346"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.3", "spread": "8.94"}]}]}, {"title": "Sitting Pulse Rate: Week 8, n=345", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "345"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.0", "spread": "9.98"}]}]}, {"title": "Sitting Pulse Rate: Week 12, n=342", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "342"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.0", "spread": "9.52"}]}]}, {"title": "Sitting Pulse Rate: Week 16, n=341", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "341"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.1", "spread": "10.08"}]}]}, {"title": "Sitting Pulse Rate: Week 20, n=338", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "338"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.3", "spread": "9.44"}]}]}, {"title": "Sitting Pulse Rate: Week 24, n=337", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "337"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.6", "spread": "9.83"}]}]}, {"title": "Sitting Pulse Rate: Week 28, n=332", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "332"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.2", "spread": "9.58"}]}]}, {"title": "Sitting Pulse Rate: Week 32, n=333", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "333"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.2", "spread": "9.74"}]}]}, {"title": "Sitting Pulse Rate: Week 36, n=329", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "329"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.6", "spread": "9.60"}]}]}, {"title": "Sitting Pulse Rate: Week 40, n=329", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "329"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.2", "spread": "9.56"}]}]}, {"title": "Sitting Pulse Rate: Week 44, n=327", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "327"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.4", "spread": "9.80"}]}]}, {"title": "Sitting Pulse Rate: Week 48, n=325", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "325"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.6", "spread": "9.65"}]}]}, {"title": "Sitting Pulse Rate: Week 52, n=322", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "322"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.1", "spread": "9.56"}]}]}, {"title": "Sitting Pulse Rate: Week 56, n=320", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "320"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.3", "spread": "9.79"}]}]}, {"title": "Sitting Pulse Rate: Week 60, n=318", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "318"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.8", "spread": "9.54"}]}]}, {"title": "Sitting Pulse Rate: Week 64, n=318", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "318"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.9", "spread": "9.63"}]}]}, {"title": "Sitting Pulse Rate: Week 68, n=317", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "317"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.2", "spread": "9.51"}]}]}, {"title": "Sitting Pulse Rate: Week 72, n=312", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "312"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.8", "spread": "10.07"}]}]}, {"title": "Sitting Pulse Rate: Week 76, n=313", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "313"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.2", "spread": "9.65"}]}]}, {"title": "Sitting Pulse Rate: Week 80, n=311", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "311"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.5", "spread": "10.08"}]}]}, {"title": "Sitting Pulse Rate: Week 84, n=310", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "310"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.2", "spread": "9.80"}]}]}, {"title": "Sitting Pulse Rate: Week 88, n=310", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "310"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.6", "spread": "10.12"}]}]}, {"title": "Sitting Pulse Rate: Week 92, n=311", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "311"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.6", "spread": "9.36"}]}]}, {"title": "Sitting Pulse Rate: Week 96, n=303", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "303"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.7", "spread": "10.61"}]}]}, {"title": "Sitting Pulse Rate: Week 100, n=300", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "300"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.5", "spread": "9.81"}]}]}, {"title": "Sitting Pulse Rate: Week 104, n=301", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "301"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.9", "spread": "10.45"}]}]}, {"title": "Sitting Pulse Rate: Week 108, n=300", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "300"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.8", "spread": "10.04"}]}]}, {"title": "Sitting Pulse Rate: Week 112, n=299", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "299"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.5", "spread": "9.60"}]}]}, {"title": "Sitting Pulse Rate: Week 116, n=297", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "297"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.5", "spread": "9.33"}]}]}, {"title": "Sitting Pulse Rate: Week 120, n=294", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "294"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.2", "spread": "10.27"}]}]}, {"title": "Sitting Pulse Rate: Week 124, n=294", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "294"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.5", "spread": "10.27"}]}]}, {"title": "Sitting Pulse Rate: Week 128, n=293", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "293"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.2", "spread": "10.00"}]}]}, {"title": "Sitting Pulse Rate: Week 132, n=289", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "289"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.7", "spread": "9.20"}]}]}, {"title": "Sitting Pulse Rate: Week 136, n=288", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "288"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.6", "spread": "10.55"}]}]}, {"title": "Sitting Pulse Rate: Week 140, n=287", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "287"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.6", "spread": "9.71"}]}]}, {"title": "Sitting Pulse Rate: Week 144, n=290", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "290"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.7", "spread": "9.72"}]}]}, {"title": "Sitting Pulse Rate: Week 148, n=287", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "287"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.8", "spread": "9.82"}]}]}, {"title": "Sitting Pulse Rate: Week 152, n=284", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "284"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.9", "spread": "10.45"}]}]}, {"title": "Sitting Pulse Rate: Week 156, n=275", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "275"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.8", "spread": "9.83"}]}]}, {"title": "Sitting Pulse Rate: Week 160, n=265", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "265"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.5", "spread": "10.42"}]}]}, {"title": "Sitting Pulse Rate: Week 164, n=242", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "242"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.1", "spread": "11.07"}]}]}, {"title": "Sitting Pulse Rate: Week 168, n=232", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "232"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.5", "spread": "11.25"}]}]}, {"title": "Sitting Pulse Rate: Week 172, n=226", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "226"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.0", "spread": "9.80"}]}]}, {"title": "Sitting Pulse Rate: Week 176, n=212", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "212"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.9", "spread": "9.57"}]}]}, {"title": "Sitting Pulse Rate: Week 180, n=200", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "200"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.5", "spread": "10.01"}]}]}, {"title": "Sitting Pulse Rate: Week 184, n=184", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "184"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.3", "spread": "9.89"}]}]}, {"title": "Sitting Pulse Rate: Week 188, n=180", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "180"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.3", "spread": "10.38"}]}]}, {"title": "Sitting Pulse Rate: Week 192, n=176", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "176"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.6", "spread": "10.37"}]}]}, {"title": "Sitting Pulse Rate: Week 196, n=175", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "175"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.2", "spread": "9.79"}]}]}, {"title": "Sitting Pulse Rate: Week 200, n=172", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "172"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.3", "spread": "11.03"}]}]}, {"title": "Sitting Pulse Rate: Week 204, n=169", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "169"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.9", "spread": "10.67"}]}]}, {"title": "Sitting Pulse Rate: Week 208, n=157", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "157"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.6", "spread": "10.64"}]}]}, {"title": "Sitting Pulse Rate: Week 212, n=146", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "146"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.4", "spread": "10.09"}]}]}, {"title": "Sitting Pulse Rate: Week 216, n=130", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "130"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.4", "spread": "10.49"}]}]}, {"title": "Sitting Pulse Rate: Week 220, n=67", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "67"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.0", "spread": "11.13"}]}]}, {"title": "Sitting Pulse Rate: Week 224, n=54", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "54"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.4", "spread": "13.19"}]}]}, {"title": "Sitting Pulse Rate: Week 228, n=37", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "37"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.4", "spread": "10.57"}]}]}, {"title": "Sitting Pulse Rate: Week 232, n=5", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.0", "spread": "16.63"}]}]}, {"title": "Sitting Pulse Rate: Follow-up, n=306", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "306"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.5", "spread": "10.72"}]}]}]}, {"type": "SECONDARY", "title": "Annualized Rate of On-treatment Exacerbations", "description": "Exacerbations were defined as worsening of asthma which required use of systemic corticosteroids and/or hospitalization and/or Emergency Department visits. Data is presented as mean which is exacerbation rate/year. Exacerbation data are performed using a negative binomial model with covariates of region, annualized rate of exacerbations in the interval between MEA112997 and MEA115666 (as an ordinal variable) and baseline % predicted FEV1, and with logarithm of time on treatment as an offset variable.", "populationDescription": "AT Population.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Exacerbations per year", "timeFrame": "Baseline (Week 0) to Week 240", "groups": [{"id": "OG000", "title": "Mepolizumab 100 mg", "description": "Participants received 100 mg of mepolizumab injected SC once every 4 weeks until participant withdrawal or mepolizumab becomes commercially available in the relevant participating country. Participants remained on standard of care asthma therapy, which was adjusted during the study, at the discretion of their physician."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "347"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.68", "lowerLimit": "0.60", "upperLimit": "0.78"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline in Asthma Control Questionnaire (ACQ) Score", "description": "The ACQ-5 is a five-item questionnaire, which was developed as a measure of participant' asthma control that was completed by the participant. The five questions enquire about the frequency and/or severity of symptoms (nocturnal awakening on waking in the morning, activity limitation, and shortness of breath, wheeze). The ACQ consists of 5 questions that are scored on a 7 point scale from 0 (totally controlled) to 6 (severely uncontrolled). The ACQ score was derived as mean of five questions: ACQ score = Question 1 (Q1)+Q2+Q3+Q4+Q5 divided by 5 where Q1, Q2,... Q5 are the scores of Q1, Q2, ..., Q5, respectively. The total score ranged from zero (no impairment/limitation) which indicated best condition to six (total impairment/ limitation) which indicated worst asthma. Baseline was Week 0. Change from Baseline was post-Baseline values minus Baseline values. Only those participants available at the specified time points were analyzed represented by n=X in the category titles.", "populationDescription": "AT Population.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a Scale", "timeFrame": "Baseline (Week 0) to Week 240", "groups": [{"id": "OG000", "title": "Mepolizumab 100 mg", "description": "Participants received 100 mg of mepolizumab injected SC once every 4 weeks until participant withdrawal or mepolizumab becomes commercially available in the relevant participating country. Participants remained on standard of care asthma therapy, which was adjusted during the study, at the discretion of their physician."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "347"}]}], "classes": [{"title": "Week 12, n=341", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "341"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.47", "spread": "0.991"}]}]}, {"title": "Week 24, n=335", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "335"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.55", "spread": "1.037"}]}]}, {"title": "Week 36, n=327", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "327"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.56", "spread": "1.088"}]}]}, {"title": "Week 48, n=324", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "324"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.55", "spread": "1.098"}]}]}, {"title": "Week 60, n=317", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "317"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.58", "spread": "1.126"}]}]}, {"title": "Week 72, n=311", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "311"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.51", "spread": "1.054"}]}]}, {"title": "Week 84, n=308", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "308"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.54", "spread": "1.090"}]}]}, {"title": "Week 96, n=301", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "301"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.44", "spread": "1.171"}]}]}, {"title": "Week 112, n=297", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "297"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.51", "spread": "1.228"}]}]}, {"title": "Week 124, n=293", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "293"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.66", "spread": "1.216"}]}]}, {"title": "Week 136, n=287", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "287"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.58", "spread": "1.215"}]}]}, {"title": "Week 148, n=286", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "286"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.54", "spread": "1.070"}]}]}, {"title": "Week 164, n=240", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "240"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.59", "spread": "1.221"}]}]}, {"title": "Week 176, n=211", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "211"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.49", "spread": "1.179"}]}]}, {"title": "Week 188, n=178", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "178"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.40", "spread": "1.310"}]}]}, {"title": "Week 200, n=171", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "171"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.45", "spread": "1.119"}]}]}, {"title": "Week 216, n=130", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "130"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.42", "spread": "1.161"}]}]}, {"title": "Week 228, n=37", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "37"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.47", "spread": "1.502"}]}]}, {"title": "Follow-up, n=301", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "301"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.53", "spread": "1.193"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline in Clinic Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1)", "description": "FEV1 is forced expiratory volume in the first second. The volume of air that can be forced out in one second after taking a deep breath, an important measure of pulmonary function. Forced expiratory volume (FEV) measures how much air a person can exhale during a forced breath. FEV1 was measured by clinic spirometry. Baseline was Week 0. Change from Baseline was post-Baseline values minus Baseline values. Only those participants available at the specified time points were analyzed represented by n=X in the category titles.", "populationDescription": "AT Population.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Milliliters (mL)", "timeFrame": "Baseline (Week 0) to Week 240", "groups": [{"id": "OG000", "title": "Mepolizumab 100 mg", "description": "Participants received 100 mg of mepolizumab injected SC once every 4 weeks until participant withdrawal or mepolizumab becomes commercially available in the relevant participating country. Participants remained on standard of care asthma therapy, which was adjusted during the study, at the discretion of their physician."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "347"}]}], "classes": [{"title": "Week 12, n=340", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "340"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "124", "spread": "346.9"}]}]}, {"title": "Week 24, n=334", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "334"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "144", "spread": "335.0"}]}]}, {"title": "Week 48, n=325", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "325"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "98", "spread": "395.2"}]}]}, {"title": "Week 72, n=312", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "312"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "91", "spread": "405.5"}]}]}, {"title": "Week 96, n=301", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "301"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "51", "spread": "385.8"}]}]}, {"title": "Week 124, n=292", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "292"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "85", "spread": "395.5"}]}]}, {"title": "Week 148, n=281", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "281"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "17", "spread": "370.2"}]}]}, {"title": "Week 176, n=210", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "210"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "45", "spread": "352.2"}]}]}, {"title": "Week 200, n=171", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "171"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "8", "spread": "375.7"}]}]}, {"title": "Week 228, n=37", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "37"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-23", "spread": "331.9"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Positive Anti-mepolizumab Binding Antibodies (ADA) and Neutralizing Antibodies (NAb)", "description": "Immunogenicity testing included two types of assays: a binding antibody assay (anti-drug antibody; ADA) and a neutralizing antibody (NAb) assay for participants who were tested positive in the ADA assay. Blood samples were collected for the determination of anti-mepolizumab antibodies, just prior to administration of mepolizumab. Samples that test positive for anti-mepolizumab antibodies were further tested for the presence of neutralizing antibody. Number of participants with positive highest value post-Baseline have been presented. Only those participants available at the specified time points were analyzed represented by n=X in the category titles.", "populationDescription": "AT Population.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Baseline (Week 0) to Week 240", "groups": [{"id": "OG000", "title": "Mepolizumab 100 mg", "description": "Participants received 100 mg of mepolizumab injected SC once every 4 weeks until participant withdrawal or mepolizumab becomes commercially available in the relevant participating country. Participants remained on standard of care asthma therapy, which was adjusted during the study, at the discretion of their physician."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "347"}]}], "classes": [{"title": "Positive ADA result, n=346", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "346"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "27"}]}]}, {"title": "Positive NAb result, n=27", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants Who Withdrew Due to Lack of Efficacy", "description": "Lack of efficacy referred to failure of expected pharmacological action of Mepolizumab. Number of participants who withdrew due to lack of efficacy are presented.", "populationDescription": "AT Population.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Baseline (Week 0) to Week 240", "groups": [{"id": "OG000", "title": "Mepolizumab 100 mg", "description": "Participants received 100 mg of mepolizumab injected SC once every 4 weeks until participant withdrawal or mepolizumab becomes commercially available in the relevant participating country. Participants remained on standard of care asthma therapy, which was adjusted during the study, at the discretion of their physician."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "347"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "11"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants Requiring Hospitalizations Due to Adverse Events Including Asthma Exacerbations", "description": "AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or is medically significant or all events of possible drug induced liver injury with hyperbilirubinemia. Number of participants requiring hospitalization due to an on-treatment serious adverse event including asthma exacerbations are presented. On-treatment SAEs are the events occurring on/after the first dose of open-label mepolizumab date and before/on last dose of mepolizumab + 28 days.", "populationDescription": "AT Population.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Baseline (Week 0) to Week 240", "groups": [{"id": "OG000", "title": "Mepolizumab 100 mg", "description": "Participants received 100 mg of mepolizumab injected SC once every 4 weeks until participant withdrawal or mepolizumab becomes commercially available in the relevant participating country. Participants remained on standard of care asthma therapy, which was adjusted during the study, at the discretion of their physician."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "347"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "71"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants Who Withdrew Due to AE", "description": "AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or is medically significant or all events of possible drug induced liver injury with hyperbilirubinemia. Number of participants who withdrew due to AE are presented.", "populationDescription": "AT Population.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Baseline (Week 0) to Week 240", "groups": [{"id": "OG000", "title": "Mepolizumab 100 mg", "description": "Participants received 100 mg of mepolizumab injected SC once every 4 weeks until participant withdrawal or mepolizumab becomes commercially available in the relevant participating country. Participants remained on standard of care asthma therapy, which was adjusted during the study, at the discretion of their physician."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "347"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "19"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "3", "timeFrame": "The on-treatment AEs and on-treatment SAEs are the events which happened on/after the first dose of open label mepolizumab date and before/on last dose of mepolizumab date + 28 days (up to 240 weeks)", "description": "AE and SAE were collected for all participants within the As Treated Population which comprised of all participants who received at least one dose of open label mepolizumab.", "eventGroups": [{"id": "EG000", "title": "Mepolizumab", "description": "Subjects will receive 100 mg of mepolizumab (in 1ml polypropylene syringe) injected subcutaneously (SC) approximately every 4 weeks.", "deathsNumAffected": 6, "deathsNumAtRisk": 347, "seriousNumAffected": 79, "seriousNumAtRisk": 347, "otherNumAffected": 314, "otherNumAtRisk": 347}], "seriousEvents": [{"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 33, "numAtRisk": 347}]}, {"term": "Pneumonia aspiration", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Respiratory arrest", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Sleep apnoea syndrome", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Status asthmaticus", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 347}]}, {"term": "Cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 347}]}, {"term": "Respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 347}]}, {"term": "Abscess limb", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Anal abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Herpes zoster", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Lower respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Myelitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Postoperative wound infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Pyelonephritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Staphylococcal infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Streptococcal infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Abdominal pain upper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Chronic gastritis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Colitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Constipation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Diverticulum intestinal", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Faecaloma", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Gastric polyps", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Incarcerated inguinal hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Inguinal hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Large intestinal obstruction", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Umbilical hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Bursitis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 347}]}, {"term": "Intervertebral disc protrusion", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 347}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Lumbar spinal stenosis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Neuropathic arthropathy", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Rheumatoid arthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Rotator cuff syndrome", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Angina unstable", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Atrial flutter", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Atrial tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Cardiac failure acute", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Comminuted fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Femur fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Joint dislocation", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Ligament rupture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Ligament sprain", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Subarachnoid haemorrhage", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Tendon rupture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Epilepsy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 347}]}, {"term": "Sciatica", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 347}]}, {"term": "Cerebral haemorrhage", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Peroneal nerve palsy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Spinal claudication", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Syncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Prostate cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 347}]}, {"term": "Basal cell carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Bladder papilloma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Breast cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Chills", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Non-cardiac chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Sudden death", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Cholelithiasis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 347}]}, {"term": "Cholestasis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Hepatocellular injury", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Hypertensive crisis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Thrombophlebitis superficial", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Anaphylactic reaction", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Anaphylactic shock", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Blood glucose increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Hepatic enzyme increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Bladder prolapse", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Renal colic", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Urinary incontinence", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Cervical polyp", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Rectocele", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Lymphocytosis", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Basedow's disease", "organSystem": "Endocrine disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Thyroid mass", "organSystem": "Endocrine disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}, {"term": "Obesity", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 347}]}], "otherEvents": [{"term": "Viral upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 169, "numAtRisk": 347}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 81, "numAtRisk": 347}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 73, "numAtRisk": 347}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 57, "numAtRisk": 347}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 43, "numAtRisk": 347}]}, {"term": "Respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 38, "numAtRisk": 347}]}, {"term": "Lower respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 31, "numAtRisk": 347}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 27, "numAtRisk": 347}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 24, "numAtRisk": 347}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 24, "numAtRisk": 347}]}, {"term": "Rhinitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 23, "numAtRisk": 347}]}, {"term": "Respiratory tract infection viral", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 20, "numAtRisk": 347}]}, {"term": "Viral infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 18, "numAtRisk": 347}]}, {"term": "Ear infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 15, "numAtRisk": 347}]}, {"term": "Acute sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 14, "numAtRisk": 347}]}, {"term": "Cystitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 13, "numAtRisk": 347}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 13, "numAtRisk": 347}]}, {"term": "Oral candidiasis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 13, "numAtRisk": 347}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 69, "numAtRisk": 347}]}, {"term": "Rhinitis allergic", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 36, "numAtRisk": 347}]}, {"term": "Oropharyngeal pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 27, "numAtRisk": 347}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 22, "numAtRisk": 347}]}, {"term": "Productive cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 12, "numAtRisk": 347}]}, {"term": "Rhinorrhoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 12, "numAtRisk": 347}]}, {"term": "Dysphonia", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 11, "numAtRisk": 347}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 11, "numAtRisk": 347}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 63, "numAtRisk": 347}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 58, "numAtRisk": 347}]}, {"term": "Pain in extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 40, "numAtRisk": 347}]}, {"term": "Osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 20, "numAtRisk": 347}]}, {"term": "Myalgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 18, "numAtRisk": 347}]}, {"term": "Musculoskeletal pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 14, "numAtRisk": 347}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 99, "numAtRisk": 347}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 23, "numAtRisk": 347}]}, {"term": "Sciatica", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 16, "numAtRisk": 347}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 26, "numAtRisk": 347}]}, {"term": "Toothache", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 22, "numAtRisk": 347}]}, {"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 17, "numAtRisk": 347}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 17, "numAtRisk": 347}]}, {"term": "Abdominal pain upper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 15, "numAtRisk": 347}]}, {"term": "Gastrooesophageal reflux disease", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 14, "numAtRisk": 347}]}, {"term": "Dyspepsia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 12, "numAtRisk": 347}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 11, "numAtRisk": 347}]}, {"term": "Injection site reaction", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 42, "numAtRisk": 347}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 12, "numAtRisk": 347}]}, {"term": "Laceration", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 15, "numAtRisk": 347}]}, {"term": "Contusion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 13, "numAtRisk": 347}]}, {"term": "Ligament sprain", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 11, "numAtRisk": 347}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 32, "numAtRisk": 347}]}, {"term": "Cataract", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 14, "numAtRisk": 347}]}, {"term": "Hypersensitivity", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 13, "numAtRisk": 347}]}, {"term": "Rash", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 12, "numAtRisk": 347}]}, {"term": "Hypercholesterolaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 11, "numAtRisk": 347}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."}, "pointOfContact": {"title": "GSK Response Center", "organization": "GlaxoSmithKline", "email": "GSKClinicalSupportHD@gsk.com", "phone": "866-435-7343"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2015-06-19", "uploadDate": "2018-04-19T08:51", "filename": "Prot_000.pdf", "size": 617403}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2017-04-06", "uploadDate": "2018-04-19T08:53", "filename": "SAP_001.pdf", "size": 817113}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}}, "hasResults": true}